DPHA — Disruptive Pharma AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK21.98m
- -SEK12.12m
Brief: Guard Therapeutics International Gets Approval To Conduct Clinical Study Of RMC-035 In Kidney Transplantation
Brief: Guard Therapeutics Q1 Loss Before Tax Widens To SEK 19.0 Million
Brief: Guard Therapeutics Q4 Pre-Tax Loss Widens To SEK 22.7 Million
Brief: Guard Therapeutics To Expand Phase 2 Study Of Rosgard To Canada
Brief: Guard Therapeutics’ Application For Phase 2 Clinical Trial Approved In Germany
Brief: Guard Therapeutics Announces Final Result Of Rights Issue
Brief: Guard Therapeutics Reports Positive Results From Preclinical Studies
Brief: Guard Therapeutics International Q3 Operating Loss Widens To SEK 34.5 Mln
Brief: Guard Therapeutics Carries Out Directed Share Issue And Rights Issue
Brief: Guard Therapeutics Reports Positive Results From Phase 1B Study
Brief: Guard Therapeutics International Proposes Johan Bygge As Chairman
Brief: Guard Therapeutics Gets Intention To Grant Notice In Europe For ROSgard
Brief: Guard Therapeutics Proposes Johan Bygge As New Chariman
Brief: Guard Therapeutics Obtains Granted Patent From USPTO Concerning ROSgard As Product
Brief: Guard Therapeutics International Q4 Pre-Tax Loss Narrows To SEK 10 Million
Brief: Guard Therapeutics Patent Granted In Australia
Brief: Guard Therapeutics Completes Pre-IND Meeting With FDA
Brief: Guard Therapeutics International - Q3 Pre-Tax Loss Sek 12.8 Million
Brief: Guard Therapeutics Q2 Pre-Tax Loss At SEK 8.7 Mln